By ANTONIO A. MARCELO, Associated PressWASHINGTON (AP) — The U.S. Food and Drug Administration said Wednesday it will delay the administration of a vaccine for the highly contagious coronavirus until after the Nov. 6 presidential election because of concerns about vaccine safety.

The FDA said it will give a “preview” of a coronaviruses vaccine to researchers and health officials next month before sending the final approval to the U.K., where it is being developed for use in the public health system.

The delay is due to concerns that the vaccine could not protect against the new coronaviral strain.

The vaccine has not been tested in humans and it has not yet been approved for use by the U and other nations.

The agency said it would allow vaccine manufacturers to conduct safety studies on the vaccine in the U., and in the UK and other countries where the vaccine is being tested.

The FDA also said it was monitoring safety issues at the vaccine site in the Netherlands.

The vaccine is intended to protect against a strain of coronavides coronavacillosis virus that causes a severe illness, including pneumonia and death.

The first vaccine was given in September to more than 100,000 people in the United States.